No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ALDX Aldeyra Therapeutics
- 3.930
- -0.010-0.25%
Close Apr 26 16:00 ET
- 3.840
- -0.090-2.29%
Post 16:34 ET
233.50MMarket Cap-6140P/E (TTM)
3.975High3.830Low267.88KVolume3.940Open3.940Pre Close1.05MTurnover0.62%Turnover RatioLossP/E (Static)59.41MShares11.97052wk High1.95P/B169.62MFloat Cap1.42052wk Low--Dividend TTM43.16MShs Float16.700Historical High--Div YieldTTM3.68%Amplitude1.420Historical Low3.913Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Aldeyra Therapeutics Unveils R&D Progress and Goals
Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host the Aldeyra 2024 Research & Development Day with investors and financial analysts in New York City to present recent pipeline developments relating to the RASP modulation platform and ADX-2191 for the treatment of retinitis pigmentosa.
Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024
PDF Version LEXINGTON, Mass.--(BUSINESS WIRE)--Apr. 18, 2024-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the tr
Aldeyra Therapeutics(ALDX.US) 10% Shareholder Buys US$833.87K in Common Stock
$Aldeyra Therapeutics(ALDX.US)$ 10% Shareholder PERCEPTIVE ADVISORS LLC purchased 177.99K shares of common stock on Apr 4, 5, 2024 at an average price of $4.68 for a total value of $833.87K. This tran
Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why
Aldeyra Therapeutics’ALDX clinical-stage immunology pipeline comprises two candidates, reproxalap and ADX-629, which are undergoing late-stage and mid-stage development, respectively.
Aldeyra Gains as Perceptive Advisors Boosts Stake
Comments
Update
$Aldeyra Therapeutics(ALDX.US$ Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day
1
ATTENTION LONG-TERM ALDEYRA THERAPEUTICS, INC. (NASDAQ: ALDX) INVESTORS
$Aldeyra Therapeutics(ALDX.US$ATTENTION LONG-TERM ALDEYRA THERAPEUTICS, INC. (NASDAQ: ALDX) INVESTORS
Grabar Law Office is investigating claims on behalf of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) shareholders. The investigation concerns whether certain officers of Aldeyra have breached their fiduciary duties owed to the company.
Current Aldeyra shareholders who have continuously held Aldeyra shares since prior to Januar...
Grabar Law Office is investigating claims on behalf of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) shareholders. The investigation concerns whether certain officers of Aldeyra have breached their fiduciary duties owed to the company.
Current Aldeyra shareholders who have continuously held Aldeyra shares since prior to Januar...
Insider buy! Almost 2M
$Aldeyra Therapeutics(ALDX.US$ 10% Shareholder PERCEPTIVE ADVISORS LLC purchased 504.27K shares of Common Stock on Apr 1, 2, 3, 2024 at an average price of $3.84 for a total value of $1.93 million.
4
6
CEO's recent share sale is viewed negatively, with no insider purchases recorded last year. Low insider ownership raises concerns about alignment with company's long-term growth. Lack of insider buying and recent selling activity make the stock less attractive.
2
Update
$Aldeyra Therapeutics(ALDX.US$ • AbbVie (NYSE:ABBV) has extended the period during which it can exercise an option for a co-development, co-commercialization and license agreement with Aldeyra Therapeutics (NASDAQ:ALDX) for dry eye candidate reproxalap.
• As a result, AbbVie (ABBV) is paying a non-refundable $5M option extension fee.
• The original option agreement was signed in late October.
• AbbVie (ABBV) now can exercise its option by the earlier of (a) the 10th business day after ...
• As a result, AbbVie (ABBV) is paying a non-refundable $5M option extension fee.
• The original option agreement was signed in late October.
• AbbVie (ABBV) now can exercise its option by the earlier of (a) the 10th business day after ...
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg